I'll have to make a distinction between the global regulatory environment and Canada.
For many countries around the world, we're still early days, and there is still uncertainty, but, to the extent that there is a trend, companies are making a distinction between products that contain foreign DNA and those that don't. When gene editing is used just to change an existing gene within a plant, it seems more likely that these will be treated like conventional products.
In Canada we have a product-based system, so our regulators are not too concerned with the methodology used but rather the trait in the final product and whether that's new and different enough to warrant a pre-market safety assessment.